Primary glomerulonephritides

The Lancet

Volumn 387, Issue 10032, 2016, Pages 2036-2048

  Floege, Jürgen ^a   Amann, Kerstin ^b  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; ALKYLATING AGENT; AZATHIOPRINE; BUDESONIDE; CALCINEURIN INHIBITOR; CHLORAMBUCIL; COMPLEMENT; CORTICOSTEROID; CORTICOTROPIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GALACTOSE; MYCOPHENOLATE MOFETIL; OFATUMUMAB; PREDNISOLONE; PREDNISONE; RITUXIMAB; STEROID; TACROLIMUS;

CHRONIC KIDNEY DISEASE; CLINICAL FEATURE; CONFERENCE PAPER; CONGENITAL NEPHROTIC SYNDROME; DIFFERENTIAL DIAGNOSIS; END STAGE RENAL DISEASE; FOCAL GLOMERULOSCLEROSIS; GLOMERULONEPHRITIDES; GLOMERULONEPHRITIS; GLOMERULOSCLEROSIS; IMMUNOGLOBULIN A NEPHROPATHY; LABORATORY TEST; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; MEMBRANOUS GLOMERULONEPHRITIS; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; ADULT; DISEASE COURSE; GLOMERULONEPHRITIS, IGA; GLOMERULONEPHRITIS, MEMBRANOPROLIFERATIVE; HUMAN; NEPHROSIS, LIPOID; PRACTICE GUIDELINE;

ADULT; DIAGNOSIS, DIFFERENTIAL; DISEASE PROGRESSION; GLOMERULONEPHRITIS; GLOMERULONEPHRITIS, IGA; GLOMERULONEPHRITIS, MEMBRANOPROLIFERATIVE; HUMANS; NEPHROSIS, LIPOID; PRACTICE GUIDELINES AS TOPIC; RISK FACTORS;

EID: 84959133193     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(16)00272-5     Document Type: Conference Paper

References (146)

1. KDIGO KDIGO clinical practice guideline for glomerulonephritis Kidney Int 2 suppl 2 2012 139 274
2. JA van den Brand, JM Hofstra, JF Wetzels Low-molecular-weight proteins as prognostic markers in idiopathic membranous nephropathy Clin J Am Soc Nephrol 6 2011 2846 2853
3. LH Beck Jr, RG Bonegio, G Lambeau et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy N Engl J Med 361 2009 11 21
4. H Kohler, E Wandel, B Brunck Acanthocyturia - a characteristic marker for glomerular bleeding Kidney Int 40 1991 115 120
5. ML Nicholson, TJ Wheatley, TM Doughman et al. A prospective randomized trial of three different sizes of core-cutting needle for renal transplant biopsy Kidney Int 58 2000 390 395
6. WL Whittier, SM Korbet Timing of complications in percutaneous renal biopsy J Am Soc Nephrol 15 2004 142 147
7. O Hergesell, H Felten, K Andrassy, K Kühn, E Ritz Safety of ultrasound-guided percutaneous renal biopsy-retrospective analysis of 1090 consecutive cases Nephrol Dial Transplant 13 1998 975 977
8. A McGrogan, CF Franssen, CS de Vries The incidence of primary glomerulonephritis worldwide: a systematic review of the literature Nephrol Dial Transplant 26 2011 414 430
9. RJ Johnson, A Hurtado, J Merszei, B Rodriguez-Iturbe, L Feng Hypothesis: dysregulation of immunologic balance resulting from hygiene and socioeconomic factors may influence the epidemiology and cause of glomerulonephritis worldwide Am J Kidney Dis 42 2003 575 581
10. SJ Barbour, DC Cattran, G Espino-Hernandez, MA Hladunewich, HN Reich Identifying the ideal metric of proteinuria as a predictor of renal outcome in idiopathic glomerulonephritis Kidney Int 88 2015 1392 1401
11. SR Orth, E Ritz, RW Schrier The renal risks of smoking Kidney Int 51 1997 1669 1677
12. M Yamaguchi, M Ando, R Yamamoto et al. Smoking is a risk factor for the progression of idiopathic membranous nephropathy PLoS One 9 2014 e100835
13. F Bonnet, C Deprele, A Sassolas et al. Excessive body weight as a new independent risk factor for clinical and pathological progression in primary IgA nephritis Am J Kidney Dis 37 2001 720 727
14. A Parsa, WH Kao, D Xie for the AASK Study Investigators and the CRIC Study Investigators APOL1 risk variants, race, and progression of chronic kidney disease N Engl J Med 369 2013 2183 2196
15. JB Kopp, CA Winkler, X Zhao for the FSGS-CT Study Consortium Clinical features and histology of apolipoprotein L1-associated nephropathy in the FSGS Clinical Trial J Am Soc Nephrol 26 2015 1443 1448
16. BI Freedman, JB Kopp, CD Langefeld et al. The apolipoprotein L1 (APOL1) gene and nondiabetic nephropathy in African Americans J Am Soc Nephrol 21 2010 1422 1426
17. WA Wilmer, BH Rovin, CJ Hebert, SV Rao, K Kumor, LA Hebert Management of glomerular proteinuria: a commentary J Am Soc Nephrol 14 2003 3217 3232
18. P Ruggenenti, E Perticucci, P Cravedi et al. Role of remission clinics in the longitudinal treatment of CKD J Am Soc Nephrol 19 2008 1213 1224
19. SJ Barbour, A Greenwald, O Djurdjev et al. Disease-specific risk of venous thromboembolic events is increased in idiopathic glomerulonephritis Kidney Int 81 2012 190 195
20. T Lee, AK Biddle, S Lionaki et al. Personalized prophylactic anticoagulation decision analysis in patients with membranous nephropathy Kidney Int 85 2014 1412 1420
21. E Gutierrez, I Zamora, JA Ballarin et al. Long-term outcomes of IgA nephropathy presenting with minimal or no proteinuria J Am Soc Nephrol 23 2012 1753 1760
22. J Floege The pathogenesis of IgA nephropathy: what is new and how does it change therapeutic approaches? Am J Kidney Dis 58 2011 992 1004
23. H Suzuki, R Fan, Z Zhang et al. Aberrantly glycosylated IgA1 in IgA nephropathy patients is recognized by IgG antibodies with restricted heterogeneity J Clin Invest 119 2009 1668 1677
24. F Berthoux, H Suzuki, L Thibaudin et al. Autoantibodies targeting galactose-deficient IgA1 associate with progression of IgA nephropathy J Am Soc Nephrol 23 2012 1579 1587
25. N Zhao, P Hou, J Lv et al. The level of galactose-deficient IgA1 in the sera of patients with IgA nephropathy is associated with disease progression Kidney Int 82 2012 790 796
26. K Kiryluk, Y Li, S Sanna-Cherchi et al. Geographic differences in genetic susceptibility to IgA nephropathy: GWAS replication study and geospatial risk analysis PLoS Genet 8 2012 e1002765
27. L Zhu, YL Zhai, FM Wang et al. Variants in complement factor H and complement factor H-related protein genes, CFHR3 and CFHR1, affect complement activation in IgA nephropathy J Am Soc Nephrol 26 2015 1195 1204
28. M Li, JN Foo, JQ Wang et al. Identification of new susceptibility loci for IgA nephropathy in Han Chinese Nat Commun 6 2015 7270
29. K Kiryluk, Y Li, F Scolari et al. Discovery of new risk loci for IgA nephropathy implicates genes involved in immunity against intestinal pathogens Nat Genet 46 2014 1187 1196
30. F Berthoux, H Mohey, B Laurent, C Mariat, A Afiani, L Thibaudin Predicting the risk for dialysis or death in IgA nephropathy J Am Soc Nephrol 22 2011 752 761
31. DC Cattran, R Coppo, HT Cook et al. The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification Kidney Int 76 2009 534 545
32. R Coppo, S Troyanov, S Bellur for the VALIGA study of the ERA-EDTA Immunonephrology Working Group Validation of the Oxford classification of IgA nephropathy in cohorts with different presentations and treatments Kidney Int 86 2014 828 836
33. H Liu, Y Peng, Y Liu et al. Renal biopsy findings of patients presenting with isolated hematuria: disease associations Am J Nephrol 36 2012 377 385
34. J Lv, Y Yang, H Zhang et al. Prediction of outcomes in crescentic IgA nephropathy in a multicenter cohort study J Am Soc Nephrol 24 2013 2118 2125
35. J Floege, J Feehally Treatment of IgA nephropathy and Henoch-Schonlein nephritis Nat Rev Nephrol 9 2013 320 327
36. V Tesar, S Troyanov, S Bellur for the VALIGA study of the ERA-EDTA Immunonephrology Working Group Corticosteroids in IgA nephropathy: a retrospective analysis from the VALIGA study J Am Soc Nephrol 26 2015 2248 2258
37. J Lv, H Zhang, Y Chen et al. Combination therapy of prednisone and ACE inhibitor versus ACE-inhibitor therapy alone in patients with IgA nephropathy: a randomized controlled trial Am J Kidney Dis 53 2009 26 32
38. C Manno, DD Torres, M Rossini, F Pesce, FP Schena Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy Nephrol Dial Transplant 24 2009 3694 3701
39. J Lv, D Xu, V Perkovic et al. Corticosteroid therapy in IgA nephropathy J Am Soc Nephrol 23 2012 1108 1116
40. F Eitner, D Ackermann, RD Hilgers, J Floege Supportive versus immunosuppressive therapy of progressive IgA nephropathy (STOP) IgAN trial: rationale and study protocol J Nephrol 21 2008 284 289
41. T Rauen, F Eitner, C Fitzner et al. Intensive supportive care plus immunosuppression in IgA nephropathy N Engl J Med 373 2015 2225 2236
42. SC Tang, AW Tang, SS Wong, JC Leung, YW Ho, KN Lai Long-term study of mycophenolate mofetil treatment in IgA nephropathy Kidney Int 77 2010 543 549
43. BD Maes, R Oyen, K Claes et al. Mycophenolate mofetil in IgA nephropathy: results of a 3-year prospective placebo-controlled randomized study Kidney Int 65 2004 1842 1849
44. G Frisch, J Lin, J Rosenstock et al. Mycophenolate mofetil (MMF) vs placebo in patients with moderately advanced IgA nephropathy: a double-blind randomized controlled trial Nephrol Dial Transplant 20 2005 2139 2145
45. RJ Hogg, RC Bay, JC Jennette et al. Randomized controlled trial of mycophenolate mofetil in children, adolescents, and adults with IgA nephropathy Am J Kidney Dis 66 2015 783 791
46. J Lv, H Zhang, Z Cui, T Su, Y Zhang, H Wang Delayed severe pneumonia in mycophenolate mofetil-treated patients with IgA nephropathy Nephrol Dial Transplant 23 2008 2868 2872
47. C Pozzi, S Andrulli, A Pani et al. Addition of azathioprine to corticosteroids does not benefit patients with IgA nephropathy J Am Soc Nephrol 21 2010 1783 1790
48. HK Smerud, B Fellstrom, R Hallgren, S Osagie, P Venge, G Kristjansson Gluten sensitivity in patients with IgA nephropathy Nephrol Dial Transplant 24 2009 2476 2481
49. HK Smerud, P Barany, K Lindstrom et al. New treatment for IgA nephropathy: enteric budesonide targeted to the ileocecal region ameliorates proteinuria Nephrol Dial Transplant 26 2011 3237 3242
50. T Kawamura, M Yoshimura, Y Miyazaki for the Special IgA Nephropathy Study Group A multicenter randomized controlled trial of tonsillectomy combined with steroid pulse therapy in patients with immunoglobulin A nephropathy Nephrol Dial Transplant 29 2014 1546 1553
51. J Floege, J Feehally The mucosa-kidney axis in IgA nephropathy Nat Rev Nephrol 2015 10.1038/nrneph.2015.208 published online Dec 30.
52. N Leeaphorn, APP Kue, N Thamcharoen, P Ungprasert, MB Stokes, EL Knight Prevalence of cancer in membranous nephropathy: a systematic review and meta-analysis of observational studies Am J Nephrol 40 2014 29 35
53. HC Stanescu, M Arcos-Burgos, A Medlar et al. Risk HLA-DQA1 and PLA(2)R1 alleles in idiopathic membranous nephropathy N Engl J Med 364 2011 616 626
54. M Fresquet, TA Jowitt, J Gummadova et al. Identification of a major epitope recognized by PLA2R autoantibodies in primary membranous nephropathy J Am Soc Nephrol 26 2015 302 313
55. L Kao, V Lam, M Waldman, RJ Glassock, Q Zhu Identification of the immunodominant epitope region in phospholipase A2 receptor-mediating autoantibody binding in idiopathic membranous nephropathy J Am Soc Nephrol 26 2015 291 301
56. NM Tomas, LH Beck Jr, C Meyer-Schwesinger et al. Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy N Engl J Med 371 2014 2277 2287
57. H Debiec, F Lefeu, MJ Kemper et al. Early-childhood membranous nephropathy due to cationic bovine serum albumin N Engl J Med 364 2011 2101 2110
58. Y Du, J Li, F He et al. The diagnosis accuracy of PLA2R-AB in the diagnosis of idiopathic membranous nephropathy: a meta-analysis PLoS One 9 2014 e104936
59. D Kanigicherla, J Gummadova, EA McKenzie et al. Anti-PLA2R antibodies measured by ELISA predict long-term outcome in a prevalent population of patients with idiopathic membranous nephropathy Kidney Int 83 2013 940 948
60. E Hoxha, I Thiele, G Zahner, U Panzer, S Harendza, RA Stahl Phospholipase A2 receptor autoantibodies and clinical outcome in patients with primary membranous nephropathy J Am Soc Nephrol 25 2014 1357 1366
61. P Ruggenenti, H Debiec, B Ruggiero et al. Anti-phospholipase A2 receptor antibody titer predicts post-rituximab outcome of membranous nephropathy J Am Soc Nephrol 26 2015 2545 2558
62. JM Hofstra, LH Beck Jr, DM Beck, JF Wetzels, DJ Salant Anti-phospholipase A receptor antibodies correlate with clinical status in idiopathic membranous nephropathy Clin J Am Soc Nephrol 6 2011 1286 1291
63. AP Bech, JM Hofstra, PE Brenchley, JF Wetzels Association of anti-PLA(2)R antibodies with outcomes after immunosuppressive therapy in idiopathic membranous nephropathy Clin J Am Soc Nephrol 9 2014 1386 1392
64. A Kattah, R Ayalon, LH Beck Jr et al. Anti-phospholipase A(2) receptor antibodies in recurrent membranous nephropathy Am J Transplant 15 2015 1349 1359
65. LH Beck Jr, FC Fervenza, DM Beck et al. Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy J Am Soc Nephrol 22 2011 1543 1550
66. E Hoxha, S Harendza, HO Pinnschmidt et al. Spontaneous remission of proteinuria is a frequent event in phospholipase A2 receptor antibody negative patients with membranous nephropathy Nephrol Dial Transplant 30 2015 1862 1869
67. N Polanco, E Gutierrez, A Covarsi et al. Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy J Am Soc Nephrol 21 2010 697 704
68. JM Hofstra, AJ Branten, JJ Wirtz, TC Noordzij, PW du Buf-Vereijken, JF Wetzels Early versus late start of immunosuppressive therapy in idiopathic membranous nephropathy: a randomized controlled trial Nephrol Dial Transplant 25 2010 129 136
69. JA van den Brand, PR van Dijk, JM Hofstra, JF Wetzels Long-term outcomes in idiopathic membranous nephropathy using a restrictive treatment strategy J Am Soc Nephrol 25 2014 150 158
70. A Howman, TL Chapman, MM Langdon et al. Immunosuppression for progressive membranous nephropathy: a UK randomised controlled trial Lancet 381 2013 744 751
71. B Dussol, S Morange, S Burtey et al. Mycophenolate mofetil monotherapy in membranous nephropathy: a 1-year randomized controlled trial Am J Kidney Dis 52 2008 699 705
72. Y Chen, A Schieppati, G Cai et al. Immunosuppression for membranous nephropathy: a systematic review and meta-analysis of 36 clinical trials Clin J Am Soc Nephrol 8 2013 787 796
73. P Ruggenenti, P Cravedi, A Chianca et al. Rituximab in idiopathic membranous nephropathy J Am Soc Nephrol 23 2012 1416 1425
74. E Hoxha, I Thiele, G Zahner, U Panzer, S Harendza, RA Stahl Phospholipase A2 receptor autoantibodies and clinical outcome in patients with primary membranous nephropathy J Am Soc Nephrol 25 2014 1357 1366
75. LC Herlitz, AS Bomback, MB Stokes, J Radhakrishnan, VD D'Agati, GS Markowitz IgA nephropathy with minimal change disease Clin J Am Soc Nephrol 9 2014 1033 1039
76. SJ Shankland, B Smeets, JW Pippin, MJ Moeller The emergence of the glomerular parietal epithelial cell Nat Rev Nephrol 10 2014 158 173
77. S Hakroush, A Cebulla, T Schaldecker, D Behr, P Mundel, A Weins Extensive podocyte loss triggers a rapid parietal epithelial cell response J Am Soc Nephrol 25 2014 927 938
78. B Smeets, F Stucker, J Wetzels et al. Detection of activated parietal epithelial cells on the glomerular tuft distinguishes early focal segmental glomerulosclerosis from minimal change disease Am J Pathol 184 2014 3239 3248
79. SS Chugh, LC Clement, C Mace New insights into human minimal change disease: lessons from animal models Am J Kidney Dis 59 2012 284 292
80. LC Herlitz, GS Markowitz, AB Farris et al. Development of focal segmental glomerulosclerosis after anabolic steroid abuse J Am Soc Nephrol 21 2010 163 172
81. LC Clement, C Avila-Casado, C Mace et al. Podocyte-secreted angiopoietin-like-4 mediates proteinuria in glucocorticoid-sensitive nephrotic syndrome Nat Med 17 2011 117 122
82. C Wei, S El Hindi, J Li et al. Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis Nat Med 17 2011 952 960
83. ET McCarthy, M Sharma, VJ Savin Circulating permeability factors in idiopathic nephrotic syndrome and focal segmental glomerulosclerosis Clin J Am Soc Nephrol 5 2010 2115 2121
84. RJ Maas, JK Deegens, JF Wetzels Permeability factors in idiopathic nephrotic syndrome: historical perspectives and lessons for the future Nephrol Dial Transplant 29 2014 2207 2216
85. D Cathelin, S Placier, M Ploug et al. Administration of recombinant soluble urokinase receptor per se is not sufficient to induce podocyte alterations and proteinuria in mice J Am Soc Nephrol 25 2014 1662 1668
86. ME Bock, HE Price, L Gallon, CB Langman Serum soluble urokinase-type plasminogen activator receptor levels and idiopathic FSGS in children: a single-center report Clin J Am Soc Nephrol 8 2013 1304 1311
87. J Huang, G Liu, YM Zhang et al. Plasma soluble urokinase receptor levels are increased but do not distinguish primary from secondary focal segmental glomerulosclerosis Kidney Int 84 2013 366 372
88. B Meijers, RJ Maas, B Sprangers et al. The soluble urokinase receptor is not a clinical marker for focal segmental glomerulosclerosis Kidney Int 85 2014 636 640
89. A Sinha, J Bajpai, S Saini et al. Serum-soluble urokinase receptor levels do not distinguish focal segmental glomerulosclerosis from other causes of nephrotic syndrome in children Kidney Int 85 2014 649 658
90. T Wada, M Nangaku, S Maruyama et al. A multicenter cross-sectional study of circulating soluble urokinase receptor in Japanese patients with glomerular disease Kidney Int 85 2014 641 648
91. EH Garin, W Mu, JM Arthur et al. Urinary CD80 is elevated in minimal change disease but not in focal segmental glomerulosclerosis Kidney Int 78 2010 296 302
92. LP Laurin, M Lu, AK Mottl, ER Blyth, CJ Poulton, KE Weck Podocyte-associated gene mutation screening in a heterogeneous cohort of patients with sporadic focal segmental glomerulosclerosis Nephrol Dial Transplant 29 2014 2062 2069
93. CE Sadowski, S Lovric, S Ashraf for the SRNS Study Group A single-gene cause in 29.5% of cases of steroid-resistant nephrotic syndrome J Am Soc Nephrol 26 2015 1279 1289
94. C Gast, RJ Pengelly, M Lyon et al. Collagen (COL4A) mutations are the most frequent mutations underlying adult focal segmental glomerulosclerosis Nephrol Dial Transplant 2015 10.1093/ndt/gfv325 published online Sept 7.
95. M Barua, E Shieh, J Schlondorff, G Genovese, BS Kaplan, MR Pollak Exome sequencing and in vitro studies identified podocalyxin as a candidate gene for focal and segmental glomerulosclerosis Kidney Int 85 2014 124 133
96. M Barua, E Stellacci, L Stella et al. Mutations in PAX2 associate with adult-onset FSGS J Am Soc Nephrol 25 2014 1942 1953
97. EH Cong, AA Bizet, O Boyer et al. A homozygous missense mutation in the ciliary gene TTC21B causes familial FSGS J Am Soc Nephrol 25 2014 2435 2443
98. RA Gbadegesin, G Hall, A Adeyemo et al. Mutations in the gene that encodes the F-actin binding protein anillin cause FSGS J Am Soc Nephrol 25 2014 1991 2002
99. G Hall, RA Gbadegesin, P Lavin et al. A novel missense mutation of Wilms' tumor 1 causes autosomal dominant FSGS J Am Soc Nephrol 26 2015 831 843
100. E Korkmaz, BS Lipska-Zietkiewicz, O Boyer et al. ADCK4-associated glomerulopathy causes adolescence-onset FSGS J Am Soc Nephrol 27 2016 63 68
101. L Li, T Zhang, W Diao et al. Role of myeloid-derived suppressor cells in glucocorticoid-mediated amelioration of FSGS J Am Soc Nephrol 26 2015 2183 2197
102. DS Gipson, H Trachtman, FJ Kaskel et al. Clinical trial of focal segmental glomerulosclerosis in children and young adults Kidney Int 80 2011 868 878
103. JK Deegens, JF Wetzels Immunosuppressive treatment of focal segmental glomerulosclerosis: lessons from a randomized controlled trial Kidney Int 80 2011 798 801
104. X Li, N Xu, H Li et al. Tacrolimus as rescue therapy for adult-onset refractory minimal change nephrotic syndrome with reversible acute renal failure Nephrol Dial Transplant 28 2013 2306 2312
105. S Choudhry, A Bagga, P Hari, S Sharma, M Kalaivani, A Dinda Efficacy and safety of tacrolimus versus cyclosporine in children with steroid-resistant nephrotic syndrome: a randomized controlled trial Am J Kidney Dis 53 2009 760 769
106. N Braun, F Schmutzler, C Lange et al. Immunosuppressive treatment for focal segmental glomerulosclerosis in adults Cochrane Database Syst Rev 3 2008 CD003233.
107. K Iijima, M Sako, K Nozu for the Rituximab for Childhood-onset Refractory Nephrotic Syndrome (RCRNS) Study Group Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial Lancet 384 2014 1273 1281
108. P Ravani, A Magnasco, A Edefonti et al. Short-term effects of rituximab in children with steroid- and calcineurin-dependent nephrotic syndrome: a randomized controlled trial Clin J Am Soc Nephrol 6 2011 1308 1315
109. A Gulati, A Sinha, SC Jordan et al. Efficacy and safety of treatment with rituximab for difficult steroid-resistant and -dependent nephrotic syndrome: multicentric report Clin J Am Soc Nephrol 5 2010 2207 2212
110. H Munyentwali, K Bouachi, V Audard et al. Rituximab is an efficient and safe treatment in adults with steroid-dependent minimal change disease Kidney Int 83 2013 511 516
111. P Ruggenenti, B Ruggiero, P Cravedi for the Rituximab in Nephrotic Syndrome of Steroid-Dependent or Frequently Relapsing Minimal Change Disease Or Focal Segmental Glomerulosclerosis (NEMO) Study Group Rituximab in steroid-dependent or frequently relapsing idiopathic nephrotic syndrome J Am Soc Nephrol 25 2014 850 863
112. A Fornoni, J Sageshima, C Wei et al. Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis Sci Transl Med 3 2011 85ra46
113. B Basu Ofatumumab for rituximab-resistant nephrotic syndrome N Engl J Med 370 2014 1268 1270
114. CC Yu, A Fornoni, A Weins et al. Abatacept in B7-1-positive proteinuric kidney disease N Engl J Med 369 2013 2416 2423
115. A Benigni, E Gagliardini, G Remuzzi Abatacept in B7-1-positive proteinuric kidney disease N Engl J Med 370 2014 1261 1263
116. EH Garin, J Reiser, G Cara-Fuentes et al. Case series: CTLA4-IgG1 therapy in minimal change disease and focal segmental glomerulosclerosis Pediatr Nephrol 30 2015 469 477
117. H Trachtman, S Vento, E Herreshoff et al. Efficacy of galactose and adalimumab in patients with resistant focal segmental glomerulosclerosis: report of the font clinical trial group BMC Nephrol 16 2015 111
118. FC Fervenza, S Sethi, RJ Glassock Idiopathic membranoproliferative glomerulonephritis: does it exist? Nephrol Dial Transplant 27 2012 4288 4294
119. S Sethi, L Zand, N Leung et al. Membranoproliferative glomerulonephritis secondary to monoclonal gammopathy Clin J Am Soc Nephrol 5 2010 770 782
120. S Sethi, FC Fervenza Membranoproliferative glomerulonephritis: pathogenetic heterogeneity and proposal for a new classification Semin Nephrol 31 2011 341 348
121. MA Abrera-Abeleda, C Nishimura, K Frees et al. Allelic variants of complement genes associated with dense deposit disease J Am Soc Nephrol 22 2011 1551 1559
122. DP Gale, EG de Jorge, HT Cook et al. Identification of a mutation in complement factor H-related protein 5 in patients of Cypriot origin with glomerulonephritis Lancet 376 2010 794 801
123. S Sethi, FC Fervenza, Y Zhang et al. Proliferative glomerulonephritis secondary to dysfunction of the alternative pathway of complement Clin J Am Soc Nephrol 6 2011 1009 1017
124. S Sethi, CM Nester, RJ Smith Membranoproliferative glomerulonephritis and C3 glomerulopathy: resolving the confusion Kidney Int 81 2012 434 441
125. Y Zhang, NC Meyer, K Wang et al. Causes of alternative pathway dysregulation in dense deposit disease Clin J Am Soc Nephrol 7 2012 265 274
126. NR Medjeral-Thomas, MM O'Shaughnessy, JA O'Regan et al. C3 glomerulopathy: clinicopathologic features and predictors of outcome Clin J Am Soc Nephrol 9 2014 46 53
127. F Bu, NG Borsa, MB Jones et al. High-throughput genetic testing for thrombotic microangiopathies and C3 glomerulopathies J Am Soc Nephrol 2015 10.1681/ASN.2015040385 published online Aug 17.
128. L Zand, EC Lorenz, FG Cosio et al. Clinical findings, pathology, and outcomes of C3GN after kidney transplantation J Am Soc Nephrol 25 2014 1110 1117
129. AS Bomback, RJ Smith, GR Barile et al. Eculizumab for dense deposit disease and C3 glomerulonephritis Clin J Am Soc Nephrol 7 2012 748 756
130. E Daina, M Noris, G Remuzzi Eculizumab in a patient with dense-deposit disease N Engl J Med 366 2012 1161 1163
131. LC Herlitz, AS Bomback, GS Markowitz et al. Pathology after eculizumab in dense deposit disease and C3 GN J Am Soc Nephrol 23 2012 1229 1237
132. Q Chen, D Muller, B Rudolph et al. Combined C3b and factor B autoantibodies and MPGN type II N Engl J Med 365 2011 2340 2342
133. Q Chen, M Wiesener, HU Eberhardt et al. Complement factor H-related hybrid protein deregulates complement in dense deposit disease J Clin Invest 124 2014 145 155
134. C Rabasco, T Cavero, E Roman et al. Effectiveness of mycophenolate mofetil in C3 glomerulonephritis Kidney Int 88 2015 1153 1160
135. V Pedchenko, O Bondar, AB Fogo et al. Molecular architecture of the Goodpasture autoantigen in anti-GBM nephritis N Engl J Med 363 2010 343 354
136. J Zhao, Z Cui, R Yang, XY Jia, Y Zhang, MH Zhao Anti-glomerular basement membrane autoantibodies against different target antigens are associated with disease severity Kidney Int 76 2009 1108 1115
137. Z Cui, J Zhao, XY Jia, SN Zhu, MH Zhao Clinical features and outcomes of anti-glomerular basement membrane disease in older patients Am J Kidney Dis 57 2011 575 582
138. S Ohlsson, H Herlitz, S Lundberg et al. Circulating anti-glomerular basement membrane antibodies with predominance of subclass IgG4 and false-negative immunoassay test results in anti-glomerular basement membrane disease Am J Kidney Dis 63 2014 289 293
139. XY Jia, SY Hu, JL Chen et al. The clinical and immunological features of patients with combined anti-glomerular basement membrane disease and membranous nephropathy Kidney Int 85 2014 945 952
140. Z Cui, J Zhao, XY Jia et al. Anti-glomerular basement membrane disease: outcomes of different therapeutic regimens in a large single-center Chinese cohort study Medicine (Baltimore) 90 2011 303 311
141. M Touzot, J Poisson, S Faguer et al. Rituximab in anti-GBM disease: a retrospective study of 8 patients J Autoimmun 60 2015 74 79
142. W Tang, SP McDonald, CM Hawley et al. Anti-glomerular basement membrane antibody disease is an uncommon cause of end-stage renal disease Kidney Int 83 2013 503 510
143. A Vizjak, D Ferluga, M Rozic et al. Pathology, clinical presentations, and outcomes of C1q nephropathy J Am Soc Nephrol 19 2008 2237 2244
144. SH Nasr, AM Valeri, LD Cornell et al. Fibrillary glomerulonephritis: a report of 66 cases from a single institution Clin J Am Soc Nephrol 6 2011 775 784
145. V Javaugue, A Karras, F Glowacki et al. Long-term kidney disease outcomes in fibrillary glomerulonephritis: a case series of 27 patients Am J Kidney Dis 62 2013 679 690
146. SC Palmer, M Sciancalepore, GF Strippoli Trial quality in nephrology: how are we measuring up? Am J Kidney Dis 58 2011 335 337